Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/Oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000-05 trial

被引：0
|
作者：
Boige, V. [1 ]
Castaing, M. [1 ]
Loriot, M. A. [2 ]
Barrois, M. [1 ]
Miran, I. [1 ]
Mulot, C. [2 ]
Pignon, J. R. [1 ]
Ducreux, M. [1 ]
Laurent-Puig, R. [2 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] INSERM, U775, Paris, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70946-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3018
引用
收藏
页码：240 / 241
页数：2
相关论文
共 50 条
  • [1] Pharmacogenetic analysis of toxicity after 5-fluorouracil (5FU) or 5FU/oxaliplatin therapy for metastatic colorectal cancer: Preliminary results in FFCD 2000-05 trial
    Castaing, M., Jr.
    Loriot, M. A.
    Barrois, M.
    Miran, I.
    Mulot, C.
    Laurent-Puig, P.
    Pignon, J. P.
    Ducreux, M.
    Boige, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Adjuvant therapy with 5-fluorouracil (5FU) plus levamisole or 5FU plus radiotherapy in resected colorectal cancer.
    Aparicio, J
    Segura, A
    Santaballa, A
    Garcerá, S
    Yuste, A
    López, P
    Tormo, A
    Reynés, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S78 - S78
  • [3] The impact of sarcopenia on toxicity and pharmacokinetics of 5-fluorouracil (5FU) in colorectal cancer.
    Williams, Grant Richard
    Deal, Allison Mary
    Shachar, Shlomit S.
    Walko, Christine Marie
    Patel, Jai Narendra
    O'Neil, Bert H.
    McLeod, Howard L.
    Weinberg, Marc
    Choi, Seul Ki
    Muss, Hyman B.
    Sanoff, Hanna Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Proteomics analysis of the effect of fluorouracil (5FU) and 5FU/leucovorin (LV) on colorectal cancer (CRC) in patients
    Smid, Kees
    Meijer, Erik
    Pham, Thang V.
    de Reus, Inge
    Piersma, Sander R.
    Peters, Godefridus J.
    Jimenez, Connie R.
    CANCER RESEARCH, 2015, 75
  • [5] Third line oxaliplatin with leucovorin (LV) and continuous infusion 5-fluorouracil (5FU) in metastatic colorectal cancer.
    Abón, G
    Muñoz, A
    Rubio, I
    Mañé, JM
    Ferreiro, J
    Fernández, R
    Fuente, N
    López-Argumedo, G
    Barceló, R
    Vivanco, GL
    ANNALS OF ONCOLOGY, 2000, 11 : 48 - 49
  • [6] Pharmacogenetic approach for capecitabine or 5-fluorouracil (5FU) selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer
    Martinez-Balibrea, E.
    Abad, A.
    Aranda, E.
    Sastre, J.
    Manzano, J. L.
    Aparicio, J.
    Garca, T.
    Maestu, I.
    Martinez-Cardus, A.
    Gines, A.
    Guino, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Preoperative chemoradiotherapy with 5-fluorouracil (5-FU) or 5-FU/oxaliplatin (5FU/OX) for rectal cancer is a feasible treatment strategy in the elderly
    Dolinsky, C. M.
    Mahmoud, N. N.
    Mick, R.
    Sun, W.
    Whittington, R.
    Solin, L. J.
    Haller, D. G.
    O'Dwyer, P.
    Fry, R. D.
    Metz, J. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S308 - S308
  • [8] Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
    Boige, Valerie
    Mendiboure, Jean
    Pignon, Jean-Pierre
    Loriot, Marie-Anne
    Castaing, Marine
    Barrois, Michel
    Malka, David
    Tregouet, David-Alexandre
    Bouche, Olivier
    Le Corre, Delphine
    Miran, Isabelle
    Mulot, Claire
    Ducreux, Michel
    Beaune, Philippe
    Laurent-Puig, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) : 2556 - 2564
  • [9] Phase II study of oxaliplatin (OHP) and protracted 5-fluorouracil (5FU) infusion in pretreated metastatic colorectal cancer (MCRC) patients
    Mini, E
    Pinto, C
    Angelelli, B
    Dentico, P
    Piana, E
    Nobili, S
    Gentile, AL
    Scicolone, S
    Mazzei, T
    Martoni, A
    ANNALS OF ONCOLOGY, 2000, 11 : 73 - 73
  • [10] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345